Erlotinib: all 574 studies that test it
Page 4 of 6. Open to participants first (10), then studies with results posted, then the rest; newest registration first within each.
- Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLCStatus unknownNCT02140333Phase 3
- Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV InfectionTerminatedNCT02134886Phase 1
- A Phase I Dose Escalation Study of Erlotinib in Combination With TheophyllineTerminatedNCT02080078Phase 1
- Intermittent and Maintenance of Erlotinib in Combination With Pemetrexed/Carboplatin in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) MutationStatus unknownNCT02066038Phase 2
- Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLCCompletedNCT02064491Phase 2
- A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib TrialCompletedNCT02057380Phase 2
- Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)WithdrawnNCT02044601Phase 1/2
- Safety and Effectiveness Study of Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With NSCLCStatus unknownNCT02037997Phase 2
- Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of stageIIIA Lung caStatus unknownNCT02036359Phase 2
- Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain TumorsStatus unknownNCT02015728Not applicable
- A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02013219Phase 1
- Evaluate Erlotinib Efficacy and Safety as the 2nd/3rd Treatment in NSCLC With EGFR M(-) and C-met(-)Status unknownNCT02006043Phase 2
- Erlotinib Intercalated With Chemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR MutationStatus unknownNCT02001896Phase 3
- Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung CancerCompletedNCT01998126Phase 1
- Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung CancerCompletedNCT01967095Phase 1
- Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant NsclcStatus unknownNCT01955421Phase 2
- Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or GefitinibWithdrawnNCT01928160Phase 2
- INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung CancerCompletedNCT01911507Phase 1
- Phase Ⅲ Trial of WBRT Versus Erlotinib Concurrent Whole-brain Radiation Therapy as first-line Treatment for Patients With Multiple Brain Metastases From Non-small-cell Lung Cancer(ENTER): a Multicentre, Open-label, Randomised StudyCompletedNCT01887795Phase 3
- A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR MutationCompletedNCT01859026Phase 1
- Paclitaxel Plus Radiation With Erlotinib to Treat Esophageal Squamous CarcinomaStatus unknownNCT01752205Phase 3
- Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic CancerStatus unknownNCT01729481Phase 2
- A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic EvaluationWithdrawnNCT01728181Phase 1/2
- Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of CancerCompletedNCT01727869Phase 1
- Erlotinib in Post Radical Operation NSCLC Patients With EGFR MutationStatus unknownNCT01683175Phase 2
- Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by SurgeryActive, not recruitingNCT01660971Phase 1
- Study of Erlotinib and Metformin in Triple Negative Breast CancerCompletedNCT01650506Phase 1
- Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.CompletedNCT01636908Not applicable
- The Role of EGFR Mutations in Pancreatic Cancer Patients Receiving Gemcitabine With or Without ErlotinibStatus unknownNCT01608841Phase 2
- A Study of LY2875358 in Japanese Participants With Advanced CancerCompletedNCT01602289Phase 1
- OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the PancreasWithdrawnNCT01600807Phase 1/2
- Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal JunctionCompletedNCT01561014Phase 1
- Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFRCompletedNCT01556191Phase 2
- Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung CancerCompletedNCT01545947Phase 1
- Erlotinib in Combination With Pralatrexate in Advanced MalignanciesCompletedNCT01532011Phase 1
- Study of Neoadjuvant Treatment in Patients With Pancreatic Cancer That is Potentially ResectableTerminatedNCT01531712Phase 2
- Whole Brain Radiation With or Without Erlotinib for Brain Metastases From Non-Small Cell Lung CancerTerminatedNCT01518621Phase 2
- Phase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC)TerminatedNCT01515969Phase 1
- Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell CarcinomaCompletedNCT01515137Phase 1
- Phase 2 Study of Erlotinib, Gemcitabine and Oxaliplatin Combination Chemotherapy to Advanced Pancreatic CancerCompletedNCT01505413Phase 2
- A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell OriginCompletedNCT01482377Phase 1
- Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung CancerTerminatedNCT01471964Phase 1/2
- Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR MutationsStatus unknownNCT01470716Phase 2
- Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)WithdrawnNCT01465815Phase 1/2
- TUSC2-nanoparticles and Erlotinib in Stage IV Lung CancerTerminatedNCT01455389Phase 1/2
- Phase 1 Trial With SIR-Spheres and Cetuximab +/- ErlotinibWithdrawnNCT01432119Phase 1
- Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR MutationsStatus unknownNCT01410214Phase 2
- Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung CancerStatus unknownNCT01407822Phase 2/3
- Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer PatientsCompletedNCT01402089Phase 4
- Efficacy and Safety of a Neoadjuvant Treatment in Pancreatic CancerCompletedNCT01389440Phase 2
- A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus ErlotinibTerminatedNCT01377376Phase 3
- Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation TherapyWithdrawnNCT01332279Phase 1
- Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung CancerSuspendedNCT01320501Phase 4
- Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell CancerCompletedNCT01316757Phase 2
- Safety and Efficacy Study of Gemcitabine-erlotinib Versus Gemcitabine-erlotinib-capecitabine in Patients With Metastatic Pancreatic CancerCompletedNCT01303029Phase 2
- A Study of LY2875358 in Participants With Advanced CancerCompletedNCT01287546Phase 1
- A Study of ARQ 197 in Combination With ErlotinibCompletedNCT01251796Phase 1
- Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer.CompletedNCT01229813Phase 3
- Erlotinib as Neoadjuvant Treatment in Patients With Stage ⅢA N2 NSCLC With Activating EGFR Mutation.CompletedNCT01217619Phase 2
- Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome ResistanceCompletedNCT01197170Phase 1
- RO4929097 and Erlotinib Hydrochloride in Treating Patients With Stage IV or Recurrent Non-small Cell Lung CancerTerminatedNCT01193881Phase 1
- Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-PaclitaxelCompletedNCT01192165Phase 1
- A Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung CancerTerminatedNCT01188707Phase 1/2
- Gemcitabine/Oxaliplatin (GEMOX) With or Without Erlotinib (Tarceva) in Advanced Biliary Tract CarcinomaCompletedNCT01149122Phase 3
- A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR MutationsStatus unknownNCT01131429Phase 2
- The Continuation of ErlotinibStatus unknownNCT01130779Phase 2
- Efficacy of Erlotinib in Neoadjuvant Setting in Patients With Stage IIIA, N2-positive Non-Small Cell Lung CancerCompletedNCT01130753Phase 2
- Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Advanced Cancers of the Aerodigestive TractCompletedNCT01116622Phase 1
- Phase I Chemoprevention Trial With Green Tea Polyphenon E & Erlotinib in Patients With Premalignant Lesions of the Head & NeckCompletedNCT01116336Phase 1
- Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).CompletedNCT01116219Phase 2
- Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant GliomaTerminatedNCT01103375Phase 1
- Erlotinib Combined With Radiotherapy in Patients With Non-resectable Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)Status unknownNCT01091376Phase 2
- Erlotinib in Higher Risk Myelodysplastic SyndromeCompletedNCT01085838Phase 1/2
- A Study of ARQ 197 in Combination With ErlotinibCompletedNCT01069757Phase 1
- A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung CancerCompletedNCT01066884Phase 4
- Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 MutationsCompletedNCT01024413Phase 3
- Erlotinib Hydrochloride in Preventing Cancer in Patients With Precancerous Lesions of the LungTerminatedNCT01013831Phase 1
- Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast CancerWithdrawnNCT01013506Phase 2
- Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic CancerCompletedNCT01010945Phase 1
- A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer SubjectsCompletedNCT01009073Phase 1
- Erlotinib for Treatment of PsoriasisWithdrawnNCT01006096Phase 2
- Study of Temsirolimus, Erlotinib and Cisplatin in Solid TumorsCompletedNCT00998036Phase 1
- A Phase 1 Protocol of 5-Azacytidine and Erlotinib in Advanced Solid Tumor MalignanciesCompletedNCT00996515Phase 1
- Study of Blood and Tissue Samples in Predicting Response to Second-Line Therapy Using Erlotinib Hydrochloride or Chemotherapy in Patients With Advanced Non-Small Cell Lung CancerStatus unknownNCT00989690Phase 3
- Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary CancerCompletedNCT00987766Phase 1
- A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung CancerTerminatedNCT00975767Phase 1
- A Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid TumorsCompletedNCT00975182Phase 1
- Phase I Study of a Statin + Erlotinib for Advanced Solid Malignancies With Focus on Squamous Cell Carcinomas and NSCLCCompletedNCT00966472Phase 1
- Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung CancerStatus unknownNCT00955695Phase 3
- Erlotinib for Chemoprevention in Trisomy 7 Positive Primary Sclerosing Cholangitis (PSC)CompletedNCT00955149Phase 1
- Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck CancerCompletedNCT00954226Phase 1
- Tarceva and AT-101 for Patients With Advanced Non-Small Cell Lung CancerWithdrawnNCT00934076Phase 1
- Trial of Erlotinib, Gemcitabine and Cisplatin in Metastatic Pancreatic CancerCompletedNCT00922896Phase 2
- Erlotinib and Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Failure of One Chemotherapy RegimenStatus unknownNCT00908336Phase 2
- An Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation StatusCompletedNCT00903734Phase 1
- Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung AdenocarcinomaStatus unknownNCT00903292Not applicable
- Tarceva/Rapamycin for Children With Low-grade Gliomas With or Without Neurofibromatosis Type 1 (NF1)CompletedNCT00901849Phase 1
- Study of Erlotinib in Combination With BortezomibCompletedNCT00895687Phase 1
- Erlotinib in Combination With CetuximabCompletedNCT00895362Phase 1
- Study of Erlotinib in Combination With DasatinibCompletedNCT00895128Phase 1